These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. The cytotoxic activity of lymphocytes from human lymph in vitro. Holm G; Franksson C; Campbell AC; Maclennan IC Clin Exp Immunol; 1974 Jul; 17(3):361-9. PubMed ID: 4466607 [TBL] [Abstract][Full Text] [Related]
24. Muscle antibodies in myasthenia gravis. Vetters JM Immunology; 1967 Sep; 13(3):275-80. PubMed ID: 4861494 [TBL] [Abstract][Full Text] [Related]
25. Myasthenia gravis: an example of receptor disease. Conti-Tronconi BM; Fumagalli G; Scotti A; Brigonzi A; Sher E; Morgutti M; Clementi F Adv Biochem Psychopharmacol; 1980; 21():473-88. PubMed ID: 7376974 [No Abstract] [Full Text] [Related]
26. Complement-mediated muscle damage produced by myasthenic sera. Childs LA; Harrison R; Lunt GG Ann N Y Acad Sci; 1987; 505():180-93. PubMed ID: 3479926 [No Abstract] [Full Text] [Related]
27. Striational antibodies in myasthenia gravis: reactivity and possible clinical significance. Romi F; Skeie GO; Gilhus NE; Aarli JA Arch Neurol; 2005 Mar; 62(3):442-6. PubMed ID: 15767509 [TBL] [Abstract][Full Text] [Related]
28. [Myasthenia gravis. Prototype of an anti-receptor autoaggression disease (author's transl)]. Hohlfeld R; Wekerle H MMW Munch Med Wochenschr; 1981 Jul; 123(31):1207-11. PubMed ID: 6790965 [TBL] [Abstract][Full Text] [Related]
29. [Considerations on HL-A antigens and their isolation]. Májský A Folia Haematol Int Mag Klin Morphol Blutforsch; 1974; 101(4):608-14. PubMed ID: 4139080 [No Abstract] [Full Text] [Related]
32. Serum lymphocytotoxic and lymphocytophilic antibody activity in inflammatory bowel disease. Korsmeyer S; Strickland RG; Wilson ID; Williams RC Gastroenterology; 1974 Oct; 67(4):578-83. PubMed ID: 4607065 [No Abstract] [Full Text] [Related]
33. Study of anti-striational and anti-thyroid antibodies in patients with myasthenia gravis. Cojocaru IM; Cojocaru M; Muşuroi C Rom J Intern Med; 2000-2001; 38-39():111-20. PubMed ID: 15529579 [TBL] [Abstract][Full Text] [Related]
34. Antibodies against muscle-specific kinase in juvenile myasthenia gravis. Anlar B; Vincent A Neuropediatrics; 2003 Apr; 34(2):110-1. PubMed ID: 12776235 [No Abstract] [Full Text] [Related]
35. Immunology of muscle disease. Penn AS; Schotland DL; Rowland LP Res Publ Assoc Res Nerv Ment Dis; 1971; 49():215-40. PubMed ID: 4947667 [No Abstract] [Full Text] [Related]
36. [Treatment with ACTH in the myasthenic syndrome with an immunological substratum]. Radu H; Roşu AM; Lenkei R; Ionescu V; Darko Z Neurol Psihiatr Neurochir; 1973; 18(4):377-84. PubMed ID: 4356514 [No Abstract] [Full Text] [Related]
37. [Immunologic aspects of the pathogenesis of myasthenia (review)]. Gekht BM Zh Nevropatol Psikhiatr Im S S Korsakova; 1968; 68(4):616-20. PubMed ID: 4879953 [No Abstract] [Full Text] [Related]
38. Plasmapheresis in the treatment of myasthenia gravis. Lenzhofer R; Graninger W; Dittrich C; Mamoli B; Zeitlhofer J; Pateisky K Wien Klin Wochenschr; 1983 Apr; 95(8):266-71. PubMed ID: 6603717 [TBL] [Abstract][Full Text] [Related]
39. Identification of autoantibodies associated with rippling muscles and myasthenia gravis that recognize skeletal muscle proteins: possible relationship of antigens and stretch-activated ion channels. Walker GR; Watkins T; Ansevin CF Biochem Biophys Res Commun; 1999 Oct; 264(2):430-5. PubMed ID: 10529381 [TBL] [Abstract][Full Text] [Related]